A M Al-Katib Selected Research

bryostatin 1

12/2001	Mitogen-activated protein kinase is required for bryostatin 1-induced differentiation of the human acute lymphoblastic leukemia cell line Reh.
1/2001	Phase II study of bryostatin 1 in patients with relapsed multiple myeloma.
1/2001	Treatment-induced expression of anti-apoptotic proteins in WSU-CLL, a human chronic lymphocytic leukemia cell line.
12/2000	The addition of bryostatin 1 to cyclophosphamide, doxorubicin, vincristine, and prednisone (CHOP) chemotherapy improves response in a CHOP-resistant human diffuse large cell lymphoma xenograft model.
4/2000	Bryostatin 1-induced modulation of nucleoside transporters and 2-chlorodeoxyadenosine influx in WSU-CLL cells.
4/2000	Sequential treatment of a resistant chronic lymphocytic leukemia patient with bryostatin 1 followed by 2-chlorodeoxyadenosine: case report.
3/2000	Phase II trial of bryostatin 1 in patients with relapsed low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia.
2/2000	Bryostatin 1 induces ubiquitination and proteasome degradation of Bcl-2 in the human acute lymphoblastic leukemia cell line, Reh.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

A M Al-Katib Research Topics

Disease

4	Neoplasms (Cancer) 01/2001 - 03/2000
4	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 01/2001 - 03/2000
2	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 12/2001 - 02/2000
2	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2001 - 03/2000
1	Lymphoid Leukemia 12/2001
1	Multiple Myeloma 01/2001
1	Diffuse Large B-Cell Lymphoma (Lymphoma, Large Cell, Diffuse) 12/2000
1	Severe Combined Immunodeficiency (Bare Lymphocyte Syndrome) 12/2000
1	Hairy Cell Leukemia 04/2000
1	Leukemia 03/2000

Drug/Important Bio-Agent (IBA)

8	bryostatin 1IBA 12/2001 - 02/2000
2	Proteins (Proteins, Gene)FDA Link 12/2001 - 02/2000
2	Protein Kinase CIBA 01/2001 - 12/2000
2	Cladribine FDA LinkGeneric 04/2000 - 04/2000
1	MitogensIBA 12/2001
1	Mitogen-Activated Protein KinasesIBA 12/2001
1	BryostatinsIBA 12/2001
1	Phosphotransferases (Kinase)IBA 12/2001
1	Mitogen-Activated Protein Kinase Kinases (MEKs)IBA 12/2001
1	fosbretabulin (combretastatin A4)IBA 01/2001
1	Apoptosis Regulatory ProteinsIBA 01/2001
1	LactonesIBA 01/2001
1	ProdrugsIBA 01/2001
1	Prednisone (Sone)FDA LinkGeneric 12/2000
1	Cyclophosphamide (Cytoxan)FDA LinkGeneric 12/2000
1	Doxorubicin (Adriamycin)FDA LinkGeneric 12/2000
1	Vincristine (Oncovin)FDA LinkGeneric 12/2000
1	fludarabineIBA 04/2000
1	Nucleoside Transport Proteins (Nucleoside Transporter)IBA 04/2000
1	purineIBA 04/2000
1	Proteasome Endopeptidase Complex (Proteasome)IBA 02/2000

Therapy/Procedure

1	Therapeutics 01/2001
1	VAP-cyclo protocol 12/2000
1	Drug Therapy (Chemotherapy) 12/2000